Iterum Therapeutics plc
ITRM
$0.9966
-$0.0534-5.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 46.76% | -57.18% | 59.18% | 28.19% | -142.87% |
| Total Depreciation and Amortization | -40.68% | -98.17% | -98.17% | -98.39% | 0.23% |
| Total Amortization of Deferred Charges | -339.25% | 331.81% | -2.57% | -1.56% | -0.68% |
| Total Other Non-Cash Items | 520.18% | 107.57% | -34.65% | -40.15% | 130.82% |
| Change in Net Operating Assets | 38.13% | -101.23% | -288.82% | -185.22% | -197.54% |
| Cash from Operations | 66.86% | 71.16% | 11.44% | -36.42% | -201.13% |
| Capital Expenditure | -- | -100.00% | 87.50% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -91.87% | 1,496.64% | -3.76% | 41.23% | 205.74% |
| Cash from Investing | -91.87% | 1,483.33% | -3.45% | 41.23% | 208.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,256.03% | 54,200.00% | -16.50% | 2,971.06% | 36.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,256.03% | 54,200.00% | -16.50% | 2,971.06% | 36.03% |
| Foreign Exchange rate Adjustments | 85.71% | -21.74% | -50.00% | -125.00% | -151.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 754.10% | 194.53% | 22.09% | 130.93% | 119.02% |